Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Standard BioTools Inc.NASDAQ: LAB
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $40K (cash outflow) fell 13.0% year over year, behind the +100.7% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -86.5% a year.
Context
- Financing cash flow amounted to 0.7% of revenue in FY2025, down 58.2 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.0% toward the trailing-twelve-month pace of +100.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 570K USD
- Year-over-year change
- +100.6%
- 4-year CAGR
- -56.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 570K | +100.6% |
| FY2024 | 2024-12-31 | (102.62M) | -1407.1% |
| FY2023 | 2023-12-31 | (6.81M) | -103.0% |
| FY2022 | 2022-12-31 | 230.76M | +1345.9% |
| FY2021 | 2021-12-31 | 15.96M | — |
Financing Cash Flow vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +100.7% is the 3rd highest of 10, against a peer median of -56.4%.
- Financing cash flow amounts to 0.7% of revenue for LAB, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $231M USD | -286.4% | +47.2% | 26.9% | |
| LTM Mar 2026 | $151.21M USD | +55.9% | — | 191.0% | |
| LTM Mar 2026 | $86.23M USD | +74.6% | — | 15.0% | |
| LTM Dec 2025 | CN¥63.7M CNY | — | +67.4% | 4.2% | |
| LTM Mar 2026 | $23.49M USD | -56.4% | -43.9% | 9.7% | |
| LTM Mar 2026 | $11.1M USD | -85.7% | — | 1.6% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $6.83M USD | -96.4% | -53.4% | 7.2% |
| LTM Mar 2026 | $2.09M USD | +107.2% | — | 1.0% | |
| LTM Mar 2026 | $1.78M USD | +2720.6% | -53.6% | 0.9% | |
| LTM Mar 2026 | $1.47M USD | -99.4% | — | — | |
| LTM Mar 2026 | $576K USD | +100.7% | -86.5% | 0.7% | |
| Peer median (excluding LAB) | — | -56.4% | -43.9% | 7.2% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Depreciation & Amortization | 16.2M | 15.03M | 15.18M | 16.86M | 1.72M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.1M | 14.88M | 13.12M | 31.73M | 29.61M |
| Change in Working Capital | (18.01M) | (12.35M) | 1.79M | (12.08M) | (44.98M) |
| Accounts Receivables | 6.73M | 1.06M | (2.99M) | 8.97M | (1.36M) |
| Inventory | (4.78M) | (8.47M) | (4.91M) | (9.88M) | (11.52M) |
| Accounts Payables | 0 | 0 | 1.62M | 0 | 2.44M |
| Other Working Capital | (19.95M) | (4.95M) | 8.07M | (11.17M) | (34.53M) |
| Other Non-Cash Items | 886K | 83.17M | 1.28M | (41.08M) | 14.2M |
| Operating Cash Flow | (44.06M) | (89.37M) | (43.29M) | (143.45M) | (74.35M) |
| Capital Expenditures | (13.26M) | (3.83M) | (2.83M) | (8.36M) | (8.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 278.65M | 0 |
| Purchases of Investments | 0 | 0 | (94.9M) | 0 | (140.93M) |
| Sales of Investments | 0 | 0 | 117.96M | 0 | 179M |
| Other Investing Activities | 1.32M | (84.3M) | 0 | 92.88M | (5M) |
| Investing Cash Flow | (11.95M) | (88.13M) | 20.24M | 363.17M | 24.77M |
| Debt Repayment | 9.5M | 18.16M | (2.08M) | (63.19M) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.05M |
| Common Stock Repurchased | (1.79M) | (774K) | (5.41M) | (40.95M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.25M | 213.37M | 827K | 1.53M | (484K) |
| Financing Cash Flow | 15.96M | 230.76M | (6.81M) | (102.62M) | 570K |
| Effect of Forex Changes | (21K) | (404K) | 34K | (785K) | 842K |
| Net Change in Cash | (40.07M) | 52.86M | (29.83M) | 116.32M | (48.17M) |
| Free Cash Flow | (57.33M) | (93.2M) | (46.12M) | (151.81M) | (82.65M) |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.